
Palatin Technologies, Inc. (AMEX:PTN) is a biopharmaceutical company focused on discovering and developing receptor-specific small molecule and peptide therapeutics, including melanocortin (MC)-based therapeutics.
The Company is evaluating further development of bremelanotide (formerly PT-141), a MC receptor agonist, for the treatment of male and female sexual dysfunction. Palatin’s patented drug discovery platform, MIDAS™, streamlines the drug discovery process with an efficient approach to creating lead compounds based on protein conformation.
|